Metabolic effects of Liraglutide in obesity v1.00
Research type
Research Study
Full title
Investigation of the metabolic effects of 3mg Liraglutide on patients with overweight or obesity.
IRAS ID
250896
Contact name
Georgios K. Dimitriadis
Contact email
Sponsor organisation
UHCW NHS Trust
Duration of Study in the UK
2 years, 10 months, 1 days
Research summary
In this study we will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and body composition), biochemical parameters, metabolomics and miRNA molecules from blood tests. Liraglutide is a commercially available analogue of a gut hormone physiologically produced in our bowel in response to food intake, approved and licenced for the treatment of overweight or obesity in UK. Liraglutide will be offered to patients attending NHS clinics within indication and according to their agreed clinical management. We aim to collect real-life information for this study as we go along with planned clinical management from patients who agree to their treatment and to take part in our study. Patients will be able to withdraw from treatment and study at any time without giving any explanation or obligation.
If successful, this study will help us combine clinical, biochemical and molecular information which will allow us to gain deeper understanding on the mechanisms behind the beneficial metabolic effects of Liraglutide in overweight and obesity. Data generated from this study will hopefully help us acquire funding for a larger multicentre study; the results of which can have substantial impact on millions of people with overweight or obesity around the world.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
18/WM/0359
Date of REC Opinion
16 Nov 2018
REC opinion
Favourable Opinion